Minireviews
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 1028-1035
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1028
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer
Muhammad Wasif Saif, Valerie Relias, Kostas Syrigos, Krishna S Gunturu
Muhammad Wasif Saif, Valerie Relias, GI Oncology Exp. Therapeutic, Tufts Medical Center-Tufts Cancer Center, Boston, MA 02111, United States
Kostas Syrigos, Oncology Unit, Third Department of Medicine, Athens Medical School, Sotiria General Hospital, Athens, Greece
Krishna S Gunturu, Lahey Clinic, Burlington, MA 02111, United States
Author contributions: Saif MW, Gunturu KS and Relias V contributed to collection of data and writing the manuscript; and Syrigos K reviewed and agreed with the manuscript.
Correspondence to: Muhammad Wasif Saif, MD, MBBS, Professor of Medicine, Tufts School of Medicine, Director, GI Onc. Program & Program leader, GI Oncology Exp. Therapeutic, Tufts Medical Center-Tufts Cancer Center, 800 Washington Street, 7-South, Suit: 7099, Boston, MA 02111, United States. wsaif@tuftsmedicalcenter.org
Telephone: +1-617-6368077 Fax: +1-617-6367060
Received: January 10, 2014
Revised: May 12, 2014
Accepted: May 29, 2014
Published online: December 10, 2014
Core Tip

Core tip: Ziv is an anti-angiogenic agent which has shown survival benefit in colorectal cancer. Side effects of this drug include hypertension, bleeding, perforation and delayed wound healing among others. In this paper, we review the side effects of Ziv and discuss how to manage those toxicities.